{"id":"https://openalex.org/W2150189780","doi":"https://doi.org/10.2147/dmso.s77290","title":"Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients","display_name":"Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients","alternate_titles":[],"publication_year":2015,"publication_date":"2015-05-01","ids":{"openalex":"https://openalex.org/W2150189780","doi":"https://doi.org/10.2147/dmso.s77290","mag":"2150189780","pmid":"https://pubmed.ncbi.nlm.nih.gov/26056482","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4445788"},"language":"en","primary_location":{"id":"doi:10.2147/dmso.s77290","doi":"https://doi.org/10.2147/dmso.s77290","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dmso.s77290","pdf_url":"https://www.dovepress.com/getfile.php?fileID=25089","source":{"id":"https://openalex.org/S176615914","display_name":"Diabetes Metabolic Syndrome and Obesity","issn_l":"1178-7007","issn":["1178-7007"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2150189780"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=25089","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074685667","display_name":"Kate Gurney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Kate Gurney","raw_affiliation_strings":["Medical Writing, Bristol-Myers Squibb, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Writing, Bristol-Myers Squibb, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018272606","display_name":"Leigh MacConell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Leigh MacConell","raw_affiliation_strings":["Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004842224","display_name":"Jaret L. Malloy","orcid":"https://orcid.org/0000-0001-6937-9854","observed_orcids":["https://orcid.org/0000-0001-6937-9854"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jaret Malloy","raw_affiliation_strings":["Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042646731","display_name":"Ming Zhou","orcid":"https://orcid.org/0000-0003-4101-3185","observed_orcids":["https://orcid.org/0000-0003-4101-3185"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ming Zhou","raw_affiliation_strings":["Biostatistics, Bristol-Myers Squibb, Princeton, NJ, USA","Biostatistics, Bristol-Myers Squibb, Princeton, nJ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Biostatistics, Bristol-Myers Squibb, Princeton, nJ,","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019395960","display_name":"Orville Kolterman","orcid":"https://orcid.org/0000-0002-9306-1288","observed_orcids":["https://orcid.org/0000-0002-9306-1288"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Orville Kolterman","raw_affiliation_strings":["Safety, Bristol-Myers Squibb, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety, Bristol-Myers Squibb, San Diego, CA, USA","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5074685667"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":5.1758,"has_fulltext":true,"cited_by_count":50,"citation_normalized_percentile":{"value":0.96461515,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"8","issue":null,"first_page":"241","last_page":"241"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/exenatide-once-weekly","display_name":"exenatide once weekly","score":0.9779999852180481},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8820000290870667},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9539999961853027},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9490000009536743},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7289999723434448},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.8960000276565552},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.9279999732971191},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.7919999957084656},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9950000047683716},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.6830000281333923},{"id":"https://openalex.org/keywords/serious-adverse-events","display_name":"serious adverse events","score":0.7379999756813049},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6019999980926514},{"id":"https://openalex.org/keywords/pancreatitis","display_name":"pancreatitis","score":0.5720000267028809},{"id":"https://openalex.org/keywords/thyroid-cancer","display_name":"thyroid cancer","score":0.8769999742507935},{"id":"https://openalex.org/keywords/kidney-failure","display_name":"renal failure","score":0.9200000166893005},{"id":"https://openalex.org/keywords/gallbladder-disease","display_name":"gallbladder disease","score":0.996999979019165}],"concepts":[{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.9884228706359863},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8617060780525208},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7759697437286377},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.7470160722732544},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7388630509376526},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4897136986255646},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.48726406693458557},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.4779812693595886},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.25791165232658386},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.170733243227005},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.06701323390007019}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.2147/dmso.s77290","doi":"https://doi.org/10.2147/dmso.s77290","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dmso.s77290","pdf_url":"https://www.dovepress.com/getfile.php?fileID=25089","source":{"id":"https://openalex.org/S176615914","display_name":"Diabetes Metabolic Syndrome and Obesity","issn_l":"1178-7007","issn":["1178-7007"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4445788","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4445788/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Metab Syndr Obes","raw_type":"Text"},{"id":"pmid:26056482","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26056482","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, metabolic syndrome and obesity : targets and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:eef3036ef72f411aa398b6c9392b9ef7","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/eef3036ef72f411aa398b6c9392b9ef7","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Diabetes, Metabolic Syndrome and Obesity, Vol 2015, Iss default, Pp 241-253 (2015)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/21781","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/safety-and-tolerability-of-exenatide-once-weekly-in-patients-with-type-peer-reviewed-article-DMSO","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.2147/dmso.s77290","doi":"https://doi.org/10.2147/dmso.s77290","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dmso.s77290","pdf_url":"https://www.dovepress.com/getfile.php?fileID=25089","source":{"id":"https://openalex.org/S176615914","display_name":"Diabetes Metabolic Syndrome and Obesity","issn_l":"1178-7007","issn":["1178-7007"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307768","display_name":"Amylin Pharmaceuticals","ror":"https://ror.org/043cec594"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2150189780.pdf","grobid_xml":"https://content.openalex.org/works/W2150189780.grobid-xml"},"referenced_works_count":70,"referenced_works":["https://openalex.org/W194251077","https://openalex.org/W1541277662","https://openalex.org/W1563830789","https://openalex.org/W1965530284","https://openalex.org/W1970638723","https://openalex.org/W1970905724","https://openalex.org/W1971478725","https://openalex.org/W1974625091","https://openalex.org/W1983929919","https://openalex.org/W1989593799","https://openalex.org/W1989713397","https://openalex.org/W1998922126","https://openalex.org/W2004409542","https://openalex.org/W2008132861","https://openalex.org/W2009288620","https://openalex.org/W2009944328","https://openalex.org/W2010976066","https://openalex.org/W2011499650","https://openalex.org/W2024569808","https://openalex.org/W2025995365","https://openalex.org/W2027276740","https://openalex.org/W2029214914","https://openalex.org/W2032398325","https://openalex.org/W2035042051","https://openalex.org/W2035321575","https://openalex.org/W2043900831","https://openalex.org/W2050984323","https://openalex.org/W2057913111","https://openalex.org/W2058683641","https://openalex.org/W2061549173","https://openalex.org/W2066987382","https://openalex.org/W2067104263","https://openalex.org/W2070710390","https://openalex.org/W2072691447","https://openalex.org/W2080509524","https://openalex.org/W2081678747","https://openalex.org/W2083357334","https://openalex.org/W2090244618","https://openalex.org/W2098459806","https://openalex.org/W2099352903","https://openalex.org/W2107949845","https://openalex.org/W2108634795","https://openalex.org/W2109677274","https://openalex.org/W2118710260","https://openalex.org/W2136259411","https://openalex.org/W2137352234","https://openalex.org/W2137805490","https://openalex.org/W2138077952","https://openalex.org/W2139485303","https://openalex.org/W2141959598","https://openalex.org/W2144028372","https://openalex.org/W2148798434","https://openalex.org/W2152835319","https://openalex.org/W2152984355","https://openalex.org/W2160088494","https://openalex.org/W2162001095","https://openalex.org/W2163502113","https://openalex.org/W2164535707","https://openalex.org/W2166534732","https://openalex.org/W2170327965","https://openalex.org/W2170606300","https://openalex.org/W2170608522","https://openalex.org/W2184287214","https://openalex.org/W4214683493","https://openalex.org/W4230892627","https://openalex.org/W4241771140","https://openalex.org/W4242364069","https://openalex.org/W4251573544","https://openalex.org/W4285719527","https://openalex.org/W4291982393"],"related_works":["https://openalex.org/W2329691248","https://openalex.org/W1969754897","https://openalex.org/W2276028032","https://openalex.org/W2913046323","https://openalex.org/W1974625091","https://openalex.org/W3086646659","https://openalex.org/W2668743363","https://openalex.org/W2158576041","https://openalex.org/W1981012218","https://openalex.org/W2010976066"],"abstract_inverted_index":{"BACKGROUND:":[0],"Exenatide":[1],"once":[2,47],"weekly":[3],"(QW)":[4],"is":[5],"a":[6,50,295],"glucagon-like":[7],"peptide-1":[8],"receptor":[9],"agonist":[10],"(GLP-1RA)":[11],"for":[12,78,122],"the":[13,31,173,234,292],"treatment":[14,26],"of":[15,36,53,104,129,134,262,269,281,294,298],"type":[16],"2":[17],"diabetes.":[18],"Safety":[19],"and":[20,33,45,49,69,84,92,112,118,126,178,198,220,238,249,259,278,300,305],"tolerability":[21,34,260,279],"are":[22],"key":[23],"considerations":[24],"in":[25,172,233,303],"selection.":[27],"This":[28],"analysis":[29],"examines":[30],"safety":[32,258,277],"profile":[35,261,280],"exenatide":[37,79,81,90,153,193,211,263,282],"QW,":[38,80,212],"other":[39,157,196,270],"approved":[40],"GLP-1RAs":[41,158,197],"(exenatide":[42],"twice":[43,82],"daily":[44],"liraglutide":[46,93],"daily),":[48],"pooled":[51,77],"population":[52],"commonly":[54],"used":[55],"non-GLP-1RA":[56,85,165,202,235,286],"treatments.":[57,142],"METHODS:":[58],"Intent-to-treat":[59],"populations":[60],"from":[61],"eight":[62],"randomized":[63],"Phase":[64],"III":[65],"trials":[66],"with":[67,108,152,156,164,181,192,201,210,240,272,285,291],"24-week":[68],"30-week":[70],"comparator-controlled":[71],"periods":[72],"were":[73,76,94,115,120,176,252],"analyzed.":[74],"Data":[75],"daily,":[83],"comparator":[86,236],"groups;":[87],"comparisons":[88],"between":[89,141],"QW":[91,154,194,264,283],"analyzed":[95,121],"separately":[96],"to":[97,145,218,267],"better":[98],"match":[99],"study":[100],"groups.":[101],"The":[102,167,256,276],"incidence":[103,114,183,297],"treatment-emergent":[105],"adverse":[106,124,127,136,146,170,187,206,308],"events":[107,125,128,137,147,171,207],"95%":[109],"confidence":[110],"intervals":[111],"exposure-adjusted":[113],"calculated.":[116],"Duration":[117],"recurrence":[119],"gastrointestinal":[123,177,274,304],"special":[130],"interest.":[131],"RESULTS:":[132],"Incidences":[133],"serious":[135],"did":[138,215],"not":[139,216],"differ":[140],"Discontinuations":[143],"due":[144],"occurred":[148,229],"numerically":[149,160,230],"less":[150],"frequently":[151,162,232],"than":[155,163,200],"but":[159,213,228],"more":[161,231],"comparators.":[166,203],"most":[168],"frequent":[169],"GLP-1RA":[174],"groups":[175],"generally":[179,214],"mild,":[180],"decreasing":[182],"over":[184,222],"time.":[185,223],"Gastrointestinal":[186],"event":[188],"incidences":[189],"appeared":[190],"lower":[191,296],"versus":[195],"greater":[199],"Injection":[204],"site-related":[205,307],"seemed":[208],"highest":[209],"lead":[217],"withdrawal":[219],"abated":[221],"Hypoglycemia":[224],"was":[225,265,288],"infrequent":[226],"overall,":[227,290],"group":[237],"increased":[239],"concomitant":[241],"sulfonylurea":[242],"use.":[243],"Pancreatitis,":[244],"thyroid":[245],"cancer,":[246],"renal":[247],"failure,":[248],"gallbladder":[250],"disease":[251],"rarely":[253],"reported.":[254],"CONCLUSION:":[255],"overall":[257],"similar":[266,289],"that":[268],"GLP-1RAs,":[271],"improved":[273],"tolerability.":[275],"compared":[284],"comparators":[287],"exception":[293],"hypoglycemia":[299],"anticipated":[301],"differences":[302],"injection":[306],"events.":[309]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2150189780","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
